Emerging Seattle-Based Sana Biotechnology Seeks to Raise $150 Million IPO

Preclinical biotech company Sana Biotechnology has filed with the U.S. Securities and Exchange Commission to raise up to $150 million in an initial public offering (IPO) to help support the company’s cell-based therapy discovery and development operations.